Chemistry:Depatuxizumab mafodotin
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric/Humanized hybrid (mouse/human) |
| Target | EGFR |
| Clinical data | |
| Other names | ABT-414 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6624H10228N1728O2052S42 |
| Molar mass | 148251.25 g·mol−1 |
Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer.[1][2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.[3][4]
This drug was developed by AbbVie. In May 2019 AbbVie stopped enrolment in all studies of Depatux-M after late-stage failure in newly diagnosed glioblastoma.[5]
In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme.[6] It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors.[7] Phase I results were presented at ASCO in 2016.[7]
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Depatuxizumab Mafodotin, American Medical Association.
- ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115". WHO Drug Information 30 (2). https://www.who.int/medicines/publications/druginformation/innlists/PL115.pdf.
- ↑ "Antibody-drug conjugates in the spotlight - The Antibody Society". 14 October 2016. http://www.antibodysociety.org/antibody-drug-conjugates-spotlight/.
- ↑ "Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments". Targeted Oncology 12 (6): 719–739. December 2017. doi:10.1007/s11523-017-0535-0. PMID 29116596.
- ↑ "AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer - PM AbbVie, May 17, 2019". abbvie.com. https://news.abbvie.com/news/press-releases/abbvie-provides-update-on-depatuxizumab-mafodotin-depatux-m-an-investigational-medicine-for-newly-diagnosed-glioblastoma-an-aggressive-form-brain-cancer.htm.
- ↑ "Depatuxizumab mafodotin". http://en.pharmacodia.com/yaodu/html/v1/biologics/1062e8784db3c431dc2a2bfb8e476131.html.
- ↑ 7.0 7.1 "Depatuxizumab mafodotin - AbbVie - AdisInsight". http://adisinsight.springer.com/drugs/800035129.
 |  |
